The evaluation of peritoneal lavage tumor markers for gastric cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15643-e15643
Author(s):  
M. Yamamoto ◽  
T. Ishida
Keyword(s):  
Gastric Cancer ◽  
Tumor Markers ◽  
Peritoneal Lavage ◽  
Peritoneal Dissemination ◽  
Stage Iv ◽  
Ca 125 ◽  
Peritoneal Carcinoma ◽  
Curative Surgery ◽  
Stage Ia ◽  
Gastric Cancer Patients

e15643 Background: We have found that elevation of preoperative peritoneal lavage CEA levels is associated with an earlier detection of recurrent peritoneal dissemination and a poor prognosis. Methods: We have now examined findings with the combined of peritoneal lavage CEA, CA125 and CA72–4 levels with regard to prediction of the prognosis of gastric cancer patients. Ninety-four patients who were underwent surgery with gastric cancer were intraoperatively measured for tumor markers, CEA, CA125 and CA72–4 in peritoneal lavage using a chemiluminescent enzyme immunoassay. We examined whether the stage with patients were related with tumor markers in peritoneal lavage. Results: The averages of peritoneal lavage CEA, CA 125 and CA72–4 levels in patients with peritoneal carcinoma were 24.3, 299, 6.70, respectively, while those in patients without peritoneal carcinoma were 0.77, 258, 0.95, respectively. The averages of peritoneal lavage CEA and CA72–4 levels in patients with peritoneal carcinoma were significantly increased with those in patients without peritoneal carcinoma (p<0.0001). In patients who were performed a curative surgery, the averages of peritoneal lavage CEA level were 0.55, 0.51, 0.51, 1.98, 0.50, 11.0 in cases of stage IA, IB, II, IIIA, IIIB and IV. Similarly, the averages of peritoneal lavage CA125 level were 254, 260, 307, 148, 366 and 280, and the average of peritoneal lavage CA72–4 level were 0.88, 1.06, 0.98, 0.90 and 3.23. The peritoneal lavage CEA or CA72–4 level in cases of stage IV was increased than in cases of other stages. The RFS of patients in the CEA level above cut-off was shorter than that in the CEA level below cut-off. However, the RFS of patients in the CA72–4 level above cut-off was not differ with that in the CA72–4 level below cut-off. In a multivariate analysis, the peritoneal lavage both CEA and CA72–4 levels above cut-off were found to be significant and independently prognostic factor (p= 0.0427). Conclusions: This combined assay of peritoneal lavage both CEA and CA72–4 levels will aid in estimating the prognosis. No significant financial relationships to disclose.

Conversion surgery of Stage IV gastric cancer with peritoneal dissemination after nivolumab

2021 ◽  
Author(s):  
Yuji Toyota ◽  
Kunio Okamoto ◽  
Norimitsu Tanaka ◽  
Hugh Shunsuke Colvin ◽  
Yuta Takahashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Dissemination ◽  
Stage Iv ◽  
Conversion Surgery ◽  
Stage Iv Gastric Cancer

scholarly journals Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection

2013 ◽  
Vol 31 (2) ◽  
pp. 605-612 ◽  
Author(s):  
TAKESHI IIDA ◽  
MAKOTO IWAHASHI ◽  
MASAHIRO KATSUDA ◽  
KOICHIRO ISHIDA ◽  
MIKIHITO NAKAMORI ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Curative Resection ◽  
Peritoneal Lavage ◽  
Prognostic Significance ◽  
Gastric Cancer Patients

scholarly journals A PHASE II TRIAL EXPLORING THE EXTENSIVE INTRA-OPERATIVE PERITONEAL LAVAGE (EIPL) AS A PROPHYLACTIC STRATEGY FOR PERITONEAL RECURRENCE IN LOCALLY ADVANCED GASTRIC CANCER: reporting postoperative morbidity and mortality after early closure

2015 ◽  
Vol 52 (2) ◽  
pp. 161-164 ◽  
Author(s):  
Thales Paulo BATISTA ◽  
Mário Rino MARTINS ◽  
Euclides Dias MARTINS-FILHO ◽  
Rogerio Luiz dos SANTOS
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Peritoneal Lavage ◽  
Locally Advanced ◽  
Open Label ◽  
Safety And Efficacy ◽  
Intention To Treat ◽  
Locally Advanced Gastric Cancer ◽  
Gastric Cancer Patients

Background The Extensive Intraoperative Peritoneal Lavage (EIPL) has been proposed as a practical prophylactic strategy to decrease the risk of peritoneal metastasis in gastric cancer. Objective To explore the safety and efficacy of the EIPL in our locally advanced gastric cancer patients. Methods This study is an open-label, double-center, single-arm phase II clinical trial developed at two tertiary hospitals from Recife (Pernambuco, Brazil). Results The study protocol was prematurely closed due to slow accrual after only 16 patients had been recruited to participate. Eight of them were excluded of the protocol study during the laparotomy, whereas four cases were also excluded from the per-protocol analysis. Two patients had died in hospital before 30 days and six were alive with no evidence of cancer relapses after a follow-up ranging from five to 14,2 months (median of 10.6 months). In the intention-to-treat analysis, three of eight patients suffered of gastrointestinal leakages and two of them had died. On a per-protocol basis, two of four patients presented this type of postoperative complication and one of them had died. All deaths occurred as a somewhat consequence of gastrointestinal leakages. Conclusion We could not make any conclusion about the safety and efficacy of the EIPL, but the possibility of this approach might increase the rate of gastrointestinal leakage is highlighted.

scholarly journals HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Agnieszka Halon ◽  
Piotr Donizy ◽  
Przemyslaw Biecek ◽  
Julia Rudno-Rudzinska ◽  
Wojciech Kielan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Test Score ◽  
Prognostic Significance ◽  
Clinicopathological Parameters ◽  
Prognostic Impact ◽  
Curative Surgery ◽  
Regional Lymph Nodes ◽  
Poorly Differentiated ◽  
Her 2 ◽  
Gastric Cancer Patients

The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P=0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient’s age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC.

scholarly journals COMPLETE REMISSION AFTER COMBINATION CHEMOTHERAPY FOR STAGE IV GASTRIC CANCER WITH PERITONEAL DISSEMINATION AND LIVER METASTASES

2003 ◽  
Vol 11 (1-2) ◽  
pp. 169-181 ◽  
Author(s):  
Masaya Mukai ◽  
Tomoya Hinoki ◽  
Takayuki Tajima ◽  
Hisao Nakasaki ◽  
Shinkichi Sato ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Complete Remission ◽  
Liver Metastases ◽  
Combination Chemotherapy ◽  
Peritoneal Dissemination ◽  
Stage Iv ◽  
Stage Iv Gastric Cancer

scholarly journals Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Koichi Hayano ◽  
Hiroki Watanabe ◽  
Takahiro Ryuzaki ◽  
Naoto Sawada ◽  
Gaku Ohira ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Stage Iv ◽  
R0 Resection ◽  
Conversion Surgery ◽  
First Line ◽  
Her2 Positive ◽  
Stage Iv Gastric Cancer ◽  
Gastric Cancer Patients ◽  
First Line Treatment

Abstract Background Since the ToGA trial, trastuzumab-based chemotherapy is the standard treatment for HER2 positive stage IV gastric cancer. However, it is not yet clear whether surgical resection after trastuzumab-based chemotherapy (conversion surgery) can improve survival of HER2 positive stage IV gastric cancer. The purpose of this study is to evaluate the prognostic benefit of conversion surgery in HER2 positive stage IV gastric cancer patients. Case presentation We retrospectively investigated the medical records of the patients with HER2 positive (IHC3(+) or IHC2(+)/FISH(+)) stage IV gastric cancer treated with trastuzumab-based chemotherapy as the first line treatment. Overall survival (OS) was compared between patients with conversion surgery and without. Eleven HER2 positive stage IV gastric cancer patients treated with trastuzumab-based chemotherapy as the first line treatment were evaluated. Response rate was 63.6%, and 6 of 11 patients could receive conversion surgery. R0 resection was achieved in four patients. In Kaplan–Meier analysis, patients who received conversion surgery showed significantly better OS than those without surgery (3-year survival rate, 66.7% vs. 20%, P = 0.03). The median OS of patients who achieved R0 resection is 51.8 months. Conclusions Conversion surgery might have a survival benefit for HER2 positive stage IV gastric cancer patients. If curative surgery is technically possible, conversion surgery could be a treatment option for HER2 positive stage IV gastric cancer.

scholarly journals Comparison of East and West Survival Nomograms in Turkish Gastric Cancer Patients Who Underwent Radical Surgery

2018 ◽  
Vol 107 (4) ◽  
pp. 308-314 ◽  
Author(s):  
Ö. Akgül ◽  
S. Ocak ◽  
S. B. Gündoğdu ◽  
M. Yalaza ◽  
C. E. Güldoğan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Confidence Interval ◽  
Survival Probability ◽  
Goodness Of Fit ◽  
Turkish Population ◽  
Curative Surgery ◽  
Goodness Of Fit Test ◽  
Resectable Gastric Cancer ◽  
East And West ◽  
Gastric Cancer Patients

Background and Aim: The clinicopathological demonstrations of gastric cancer vary widely between Eastern and Western countries. Turkey is situated in Europe and Middle East which acts as a bridge between east and west. We aimed to validate the two popular nomograms of east and west origin by means of patients who underwent curative surgery for gastric cancer in our country. Material and Methods: Of the 202 patients diagnosed with gastric cancer between the years 2006 and 2013, 145 of these patients whose data were sufficient were included in the study. For all patients, demographic, laboratory, operative, and pathologic findings were documented. For each patient, prognostic factors were incorporated into the nomograms for estimating 5-year survival probability. Results: For a Turkish cohort, the western nomogram showed a better discriminative capacity (AUC = 0.721, 95% confidence interval 0.637–0.806) and was better calibrated (the Hosmer–Lemeshow goodness-of-fit test p = 0.323), as compared to the eastern nomogram with AUC = 0.615, 95% confidence interval 0.522–0.708, and p = 0.077, respectively. Conclusion: Western nomogram was found to be more effective than eastern nomogram in prediction of estimating 5-year survival probability in patients with resectable gastric cancer in Turkish population.

Prognostic Indicators in Stage IV Surgically Treated Gastric Cancer Patients: A Retrospective Multi-Institutional Study

2018 ◽  
Vol 36 (4) ◽  
pp. 331-339
Author(s):  
Alberto Biondi ◽  
Domenico D’Ugo ◽  
Ferdinando Cananzi ◽  
Stefano Rausei ◽  
Federico Sicoli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Residual Disease ◽  
Stage Iv ◽  
Long Term Results ◽  
Stage Iv Gastric Cancer ◽  
Short And Long Term ◽  
Gastric Cancer Patients

Introduction: The role of gastric resection in treating metastatic gastric adenocarcinoma is controversial. In the present study, we reviewed the short- and long-term outcomes of stage IV patients undergoing surgery. Methods: A retrospective review was conducted that assessed patients undergoing elective surgery for incurable gastric carcinoma. Short- and long-term results were evaluated. Results: A total of 122 stage IV gastric cancer patients were assessed. Postoperative mortality was 5.7%, and the overall rate of complications was 35.2%. The overall survival rate at 1 and 3 years was 58 and 19% respectively; the median survival was 14 months. Improved survival was observed for the factors age less than 60 years (p = 0.015), site of metastases (p = 0.022), extended lymph node dissection (p = 0.044), absence of residual disease after surgery (p = 0.001), and administration of adjuvant chemotherapy (p = 0.016). Multivariate analysis showed that residual disease and adjuvant chemotherapy were independent prognostic factors. Conclusions: The results of this study suggest that surgery combined with systemic chemotherapy in selected patients with stage IV gastric cancer can improve survival.

Sign in / Sign up

Export Citation Format

Share Document